Effectiveness of magnesium on endothelial function in CKD stage G4 patients: A Randomized Control Trial
Article Sidebar
Main Article Content
Abstract
Background: Vascular endothelial dysfunction is associated with cardiovascular complications. Magnesium can improve vascular endothelial function but the evidence in advanced stage chronic kidney disease (CKD) is not clear. This study investigates the effect of magnesium on vascular endothelial function in CKD stage G4 patients
Method: We randomly assigned 21 CKD stage G4 patients to receive magnesium supplement or standard treatment without magnesium supplement for 6 months. The primary outcome was the change in flow mediated dilatation. Secondary outcomes were the change in blood pressure at 6 months and the occurrence of adverse events.
Results: Ten of 21 patients were randomized to standard treatment without magnesium supplement and 11 patients were randomized to magnesium supplement. Median changes in the flow mediated dilatation were -2.35 (IQR 10.06) in the control group and -2.4 (IQR 15.06) in the treatment group (P=NS). The was no significant difference in the mean change of systolic blood pressure in either group (P=0.77). The mean diastolic blood pressure increased in the control group (2.6 mmHg, SD ±2.2) and decreased in treatment group (-13.45 mmHg, SD±3.8) (P=0.002). There was no adverse event in either group.
Conclusion: There was no benefit of magnesium supplement on vascular endothelial function and systolic blood pressure in patients with CKD stage G4. However, a substantial reduction in the diastolic blood pressure was noted in the treatment group.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This article is published under CC BY-NC-ND 4.0 license, which allows for non-commercial reuse of the published paper as long as the published paper is fully attributed. Anyone can share (copy and redistribute) the material in any medium or format without having to ask permission from the author or the Nephrology Society of Thailand.
References
Michiels C. Endothelial cell functions. J Cell Physiol.2003; 196(3):430–43.
Lerman Amir, Zeiher Andreas M. Endothelial Function. Circulation. 2005;111(3):363–8.
Grover-Páez F, Zavalza-Gómez AB. Endothelial dysfunction and cardiovascular risk factors. Diabetes Res Clin Pract. 2009;84(1):1–10.
Favarato D, da Luz PL. Chapter 34 - Endothelial Function and Cardiovascular Risk Factors. In: Da Luz PL, Libby P, Chagas ACP, Laurindo FRM, editors. Endothelium and Cardiovascular Diseases [Internet]. Academic Press; 2018 [cited 2021 Apr 18]. p. 513–26. Available from: https://www.sciencedirect.com/science/article/pii/B9780128123485000349
Wu-Wong JR. Endothelial dysfunction and chronic kidney disease: treatment options. Curr Opin Investig Drugs Lond Engl 2000. 2008;9(9):970–82.
Annuk M, Soveri I, Zilmer M, Lind L, Hulthe J, Fellström B. Endothelial function, CRP and oxidative stress in chronic kidney disease. J Nephrol. 2005;18(6):721–6.
Zoccali C. Endothelial Dysfunction and the Kidney: Emerging Risk Factors for Renal Insufficiency and Cardiovascular Outcomes in Essential Hypertension. J Am Soc Nephrol. 2006;17(4 suppl 2):S61–3.
Recio-Mayoral A, Banerjee D, Streather C, Kaski JC. Endothelial dysfunction, inflammation and atherosclerosis in chronic kidney disease--a cross-sectional study of predialysis, dialysis and kidney-transplantation patients. Atherosclerosis. 2011;216(2):446–51.
Su JB. Vascular endothelial dysfunction and pharmacological treatment. World J Cardiol. 2015;7(11):719–41.
ter Braake Anique D., Shanahan Catherine M., de Baaij Jeroen H.F. Magnesium Counteracts Vascular Calcification. Arterioscler Thromb Vasc Biol. 2017;37(8):1431–45.
Wolf FI, Trapani V, Simonacci M, Ferré S, Maier JA. Magnesium deficiency and endothelial dysfunction: is oxidative stress involved? Magnes Res. 2008;21(1):58–64.
Kostov K, Halacheva L. Role of Magnesium Deficiency in Promoting Atherosclerosis, Endothelial Dysfunction, and Arterial Stiffening as Risk Factors for Hypertension. Int J Mol Sci. 2018;19(6):1724.
Pearson PJ, Evora PR, Seccombe JF, Schaff HV. Hypomagnesemia inhibits nitric oxide release from coronary endothelium: protective role of magnesium infusion after cardiac operations. Ann Thorac Surg. 1998;65(4):967–72.
Massy ZA, Drüeke TB. Magnesium and outcomes in patients with chronic kidney disease: focus on vascular calcification, atherosclerosis and survival. Clin Kidney J.2012;5(Suppl_1):i52–61.
Flammer Andreas J., Anderson Todd, Celermajer David S., Creager Mark A., Deanfield John, Ganz Peter, et al. The Assessment of Endothelial Function. Circulation. 2012;126(6):753–67.
Tanaka Atsushi, Tomiyama Hirofumi, Maruhashi Tatsuya, Matsuzawa Yasushi, Miyoshi Toru, Kabutoya Tomoyuki, et al. Physiological Diagnostic Criteria for Vascular Failure. Hypertension. 2018;72(5):1060–71.
Cunha AR, D’El-Rei J, Medeiros F, Umbelino B, Oigman W, Touyz RM, et al. Oral magnesium supplementation improves endothelial function and attenuates subclinical atherosclerosis in thiazide-treated hypertensive women. J Hypertens. 2017;35(1):89–97.
Sakaguchi Y, Hamano T, Obi Y, Monden C, Oka T, Yamaguchi S, et al. A Randomized Trial of Magnesium Oxide and Oral Carbon Adsorbent for Coronary Artery Calcification in Predialysis CKD. J Am Soc Nephrol JASN. 2019;30(6):1073–85.
Stout M. Flow-mediated dilatation: a review of techniques and applications. Echocardiogr Mt Kisco N. 2009;26(7):832–41.
Thijssen DHJ, Black MA, Pyke KE, Padilla J, Atkinson G, Harris RA, et al. Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. Am J Physiol - Heart Circ Physiol. 2011;300(1):H2–12.
Thai HT Guideline 2019.pdf [Internet]. [cited 2021 Apr 18]. Available from: http://www.thaiheart.org/images/column_1563846428/Thai%20HT%20Guideline%202019.pdf
CKD Evaluation and Management – KDIGO [Internet]. [cited 2021 Apr 18]. Available from: https://kdigo.org/guidelines/ckd-evaluation-and-management/